文献速递真菌感染医院感染防控

中国接受异基因造血干细胞移植患者的侵袭性真菌病:多中心流行病学研究(CAESAR 2.0)

Invasive Fungal Disease in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation in China: A Multicenter Epidemiological Study (CAESAR 2.0).
PubMed 文献 · Clin Infect Dis · 2025-01-01

该多中心、真实世界观察性研究在中国12家异基因造血干细胞移植中心于2021年1月至12月纳入2015例接受抗真菌预防的成人患者,随访至2022年12月31日。移植后1年侵袭性真菌病(确诊或临床诊断)累积发病率为6.3%,归因死亡率为48.28%;多因素分析显示晚期疾病、III-IV级急性移植物抗宿主病与侵袭性真菌病风险升高相关,而中性粒细胞和血小板植入(≤28天)与风险降低相关。

要点

  • 移植后1年侵袭性真菌病累积发病率为6.3%,归因死亡率为48.28%。
  • 76.08%患者使用覆盖霉菌的预防,其中伏立康唑44.37%、泊沙康唑31.71%。
  • 晚期疾病(HR 2.55)和III-IV级急性移植物抗宿主病(HR 2.97)与侵袭性真菌病风险升高相关。

核心结论

  • 尽管广泛使用覆盖霉菌的预防,异基因造血干细胞移植后侵袭性真菌病风险仍高。
  • 最常见病原体为念珠菌属、毛霉目、曲霉属和耶氏肺孢子菌。

研究设计与样本

  • 多中心、真实世界、观察性研究,在中国12家异基因造血干细胞移植中心开展。
  • 研究时段为2021年1月至12月,随访至2022年12月31日完成。
  • 连续纳入接受抗真菌预防的成人(年龄≥18岁)异基因造血干细胞移植患者,共2015例。
  • 侵袭性真菌病按欧洲癌症研究与治疗组织和真菌病研究组(EORTC/MSG)2019年标准诊断。

主要发现

  • 移植后1年侵袭性真菌病(确诊或临床诊断)累积发病率为6.3%。
  • 76.08%患者使用覆盖霉菌的预防,其中伏立康唑44.37%、泊沙康唑31.71%。
  • 47.97%的侵袭性真菌病病例鉴定出病原体,主要为念珠菌属(17.89%)、毛霉目(13.01%)、曲霉属(8.94%)和耶氏肺孢子菌(6.5%)。
  • 多因素分析显示:晚期疾病(风险比2.55 [95%置信区间1.58-4.12];P<.001)、中性粒细胞绝对计数植入≤28天(0.37 [15-.92];P=.03)、血小板植入≤28天(0.41 [.27-.62];P<.001)、III-IV级急性移植物抗宿主病(2.97 [1.97-4.49];P<.001)与侵袭性真菌病相关。
  • 侵袭性真菌病归因死亡率为48.28%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: This study (China Assessment of Antifungal Therapy in Hematological Diseases [CAESAR 2.0]) aimed to provide updated epidemiological data on invasive fungal disease (IFD) in patients undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT). METHODS: This multicenter, real-world, observational study was conducted at 12 allo-HSCT centers in China between January and December 2021. Consecutive adult patients (aged ≥18 years) who underwent allo-HSCT with antifungal prophylaxis were included. IFD was diagnosed according to the 2019 criteria of the European Organization for Research and Treatment of Cancer and Mycoses Study Group (EORTC/MSG). Follow-up was completed by 31 December 2022. RESULTS: A total of 2015 patients were included. Mold-active antifungal prophylaxis was used in 76.08%, most of whom received voriconazole (44.37%) or posaconazole (31.71%). The cumulative incidence of IFD (proven or probable) 1 year after allo-HSCT was 6.3%. Pathogens were identified in 47.97% of IFD cases and mainly included Candida spp. (17.89%), Mucorales (13.01%), Aspergillus spp. (8.94%), and Pneumocystis jirovecii (6.5%). Multivariate analysis identified the following factors associated with IFD: disease at advanced stage (hazard ratio, 2.55 [95% confidence interval, 1.58-4.12]; P < .001), absolute neutrophil count engraftment (≤28 days) (0.37 [15-.92]; P = .03), platelet engraftment (≤28 days) (0.41 [.27-.62]; P < .001), and acute graft-vs-host disease grade III-IV (2.97 [1.97-4.49]; P < .001). The IFD-attributable mortality rate was 48.28%. CONCLUSIONS: Despite the widespread use of mold-active prophylaxis, the risk of IFD after allo-HSCT remains high. The most common pathogens are Candida spp., Mucorales, Aspergillus spp., and P. jirovecii.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Li C, Zhu DP, Chen J, et al. Invasive Fungal Disease in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation in China: A Multicenter Epidemiological Study (CAESAR 2.0). Clin Infect Dis. 2025. PMID: 39666951. doi:10.1093/cid/ciae612

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。